Hidradenitis suppurativa
Hidradenitis suppurativa Market

Hidradenitis suppurativa

Hidradenitis Suppurativa is a complex dermatological disease characterized by recurrent painful nodules and suppuration in areas such as the axilla and groin. It is also known as Acne inversa and there is no biological or pathological test to facilitate diagnosis; it can be defined by its clinical features and its chronicity.


Hidradenitis suppurativa Epidemiology Segmentation in the 7MM


  • Total Prevalent Pool
  • Diagnosed Pool
  • Gender-specific Prevalent Pool
  • Age-specific Prevalent Pool
  • Stage-specific Prevalent Pool
  • Treated Moderate to Severe Prevalent Pool


Hidradenitis suppurativa Epidemiological Insights Observed in the 7MM (2021)

  • The total number of incident cases of Hidradenitis suppurativa observed in the 7MM was observed to be 1 million in the year 2021
  • The highest diagnosed Hidradenitis suppurativa population accounting for 572K cases, was found in the United States, followed by EU5 (572K) and Japan (90K) in the year 2021. 


Hidradenitis suppurativa Market Insight

The market size of Hidradenitis suppurativa in the 7MM was found to be approximately USD 899 million in 2021


Hidradenitis suppurativa Market Strengths

The increasing population of cocaine users and increasing episodes of Hidradenitis suppurativa worldwide likely cause a surge in treatment options. Consequently, the market will witness a boost in the upcoming year. 


Hidradenitis suppurativa Market Opportunities

Various big Pharma key players are currently active in the development of a novel drug for the treatment of MG.


´╗┐Hidradenitis suppurativa Emerging Drugs and Key Companies


  • VILOBELIMAB (IFX-1): INFLARX
  • COSENTYX (SECUKINUMAB): NOVARTIS PHARMACEUTICALS
  • INCB054707: INCYTE CORPORATION
  • SKYRIZI (RISANKIZUMAB): ABBVIE
  • BIMZELX (BIMEKIZUMAB): UCB BIOPHARMA SPRL
  • BERMEKIMAB: JANSSEN PHARMACEUTICALS
  • CFZ533 (ISCALIMAB), LYS006 AND MAS825: NOVARTIS PHARMACEUTICALS
  • OTEZLA (APREMILAST): AMGEN
  • TAVNEOS (AVACOPAN): CHEMOCENTRYX
  • BREPOCITINIB (PF-06700841): PRIOVANT THERAPEUTICS/PFIZER
  • IMSIDOLIMAB (ANB019): ANAPTYSBIO
  • LUTIKIZUMAB (ABT-981): ABBVIE
  • IZOKIBEP: ACELYRIN
  • ZUNSEMETINIB (ATI-450): ACLARIS THERAPEUTICS
  • SPESOLIMAB: BOEHRINGER INGELHEIM
  • LY3041658: ELI LILLY
  • SONELOKIMAB (M1095): MOONLAKE IMMUNOTHERAPEUTICS
  • RUXOLITINIB: INCYTE CORPORATION
  • RIST4721: ARISTEA THERAPEUTICS, and others